Doxycycline should not normally be used for STI post-exposure prophylaxis

Doxycycline should not normally be used for STI post-exposure prophylaxis

November 10 2017 Doxycycline should not be used for post-exposure prophylaxis (PEP) for sexually...

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

October 31 2017 The medicines regulator has issued four drug safety updates (DRU) relating to...

Pneumococcal polysaccharide vaccine shortage prompts advice about prioritisation

Pneumococcal polysaccharide vaccine shortage prompts advice about prioritisation

October 23 2017 A shortage of the pneumococcal polysaccharide vaccine has promoted a Chief...

PHE issues guide on sepsis in children for health visitors and school nurses

PHE issues guide on sepsis in children for health visitors and school nurses

October 10 2017 A new guide setting out information around sepsis in children has been published...

MHRA issues Drug Safety Updates for loperamide and miconazole

MHRA issues Drug Safety Updates for loperamide and miconazole

October 4 2017 The medicines regulator, the MHRA, has issued Drug Safety Updates on two...

  • Doxycycline should not normally be used for STI post-exposure prophylaxis

    Doxycycline should not normally be used for STI post-exposure prophylaxis

    Friday, 10 November 2017 17:31
  • MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    Tuesday, 31 October 2017 20:27
  • Pneumococcal polysaccharide vaccine shortage prompts advice about prioritisation

    Pneumococcal polysaccharide vaccine shortage prompts advice about prioritisation

    Monday, 23 October 2017 09:39
  • PHE issues guide on sepsis in children for health visitors and school nurses

    PHE issues guide on sepsis in children for health visitors and school nurses

    Tuesday, 10 October 2017 13:34
  • MHRA issues Drug Safety Updates for loperamide and miconazole

    MHRA issues Drug Safety Updates for loperamide and miconazole

    Wednesday, 04 October 2017 17:04

a alert imageOctober 31 2017

The medicines regulator has issued four drug safety updates (DRU) relating to gabapentin methylprednisolone clozapine isotretinoin.

The MHRA’s warning on gabapentin says the people taking the drug, used in epilepsy and peripheral neuropathic pain, have “a rare risk of severe respiratory depression even without concomitant opioid medicines.” Dose adjustments may be necessary in a number of patient groups: those with compromised respiratory function; respiratory or neurological disease; renal impairment; concomitant use of central nervous system (CNS) depressants; and the elderly.

The warning around methylprednisolone relates to Solu-Medrone 40mg injection. This strength uses lactose produced from cows’ milk as an excipient and may contain trace amounts of milk proteins.

“Do not use injectable methylprednisolone medicines that contain lactose in patients with a known or suspected allergy to cows’ milk,” says the DSU. “If a patient’s symptoms worsen or any new allergic symptoms occur, allergic reaction to cows’ milk proteins should be suspected; stop administration of the product and treat the patient’s condition accordingly.”

Constipation occurring with clozapine needs to be monitored, says the third DSU. The antipsychotic has been associated with varying degrees of impairment of intestinal peristalsis, ranging from “constipation, which is very common, to very rare intestinal obstruction, faecal impaction, and paralytic ileus.”

Particular care is needed in patients who taking other drugs known to cause constipation, in patients with a history of colonic disease or lower abdominal surgery, or in patients aged 60 years and older. Clozapine should not be used in patients with paralytic ileus.

Patients who develop constipation should report it immediately, and health professionals should “actively treat any constipation that occurs.”

The isotretinoin DSU advises that there have been some reports of sexual dysfunction, especially erectile dysfunction and loss of libido, in patients taking oral isotretinoin for severe acne. “The exact incidence of these adverse reactions is unknown but considering the number of patients in the UK taking the medicine, reports are understood to be rare,” says the MHRA.

For all drugs, the MHR is asking that any suspected adverse reactions be reported using eth Yellow Card scheme.

Links:
MHRA DSU on gabapentin           
MHRA DSU on methylprednisolone           
MHRA DSU on clozapine                 
MHRA DSU on isotretinoin            
Yellow Card scheme         

 

Clinical News

November 21 2017 Recruitment into GP training places in Wales has passed the target set for this year. The Wales Deanery has said that 144 GP training places have been filled, passing the target of...
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...